Cardiovascular Monitoring With Trastuzumab Therapy: How Frequent Is Too Frequent?

Trastuzumab has led to meaningful improvements in survival in early-stage and metastatic ERBB2 (formerly HER2 or HER2/neu)-positive breast cancer.^1,2 Trastuzumab is generally well tolerated but is associated with infrequent cardiac dysfunction, manifested most often as an asymptomatic decline in left ventricular ejection fraction (LVEF).^1-6